Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 121 results
May 2019
-
Key ReleaseFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancerPiqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
-
Key ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and FamiliesOne-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD…
-
Key ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
-
Key ReleaseNovartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye careXiidra (lifitegrast ophthalmic solution) 5% fits strategically within industry-leading USD 4.6 billion Novartis ophthalmic pharmaceutical portfolio, laying groundwork for front-of-the-eye pipeline…
March 2019
-
Key ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseMayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
Key ReleaseNovartis plans for Alcon spin-off on April 9, 2019Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
-
Key ReleaseNovartis announces change in Sandoz leadershipRichard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- › Next page